BRVE (Braveheart Bio) OCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BRVE Braveheart Bio Inc BRVE
8 GF Score
Price $31.93
View Full Analysis

What is Braveheart Bio OCF Margin %?

Braveheart Bio BRVE -2.72% 8 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates BRVE with a GF Score™ of 8/100. Among 954 Biotechnology companies, Braveheart Bio ranks worse than 104821.7% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Braveheart Bio's Cash Flow from Operations for the six months ended in Dec. 2025 was $-2.01 Mil. Braveheart Bio's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Braveheart Bio's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Braveheart Bio's current OCF Yield % is -16,900.00%.

The historical rank and industry rank for Braveheart Bio's OCF Margin % or its related term are showing as below:


BRVE's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.67
* Ranked among companies with meaningful OCF Margin % only.

Braveheart Bio OCF Margin % Related Terms

Braveheart Bio OCF Margin % Historical Data

* Premium members only.

The historical data trend for Braveheart Bio's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Braveheart Bio OCF Margin % Chart

Braveheart Bio Annual Data
Trend Dec25
OCF Margin %
0.00

Braveheart Bio Semi-Annual Data
Dec25
OCF Margin % 0.00
BRVE
8GF Score
Braveheart Bio Inc BRVE
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Braveheart Bio OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Braveheart Bio's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2.014/0
= %

Braveheart Bio's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.014/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Braveheart Bio (BRVE) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Braveheart Bio and its competitors. According to the industry distribution chart, Braveheart Bio ranks #999999 out of 954 companies in the Biotechnology industry.
Is Braveheart Bio's OCF Margin % too high?
Braveheart Bio's current OCF Margin % is 0.00%. Based on the distribution chart, Braveheart Bio ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Braveheart Bio has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Braveheart Bio's OCF Margin % compare to ?
According to the Biotechnology industry distribution chart, Braveheart Bio ranks #999999 out of 954 companies for OCF Margin %. This places Braveheart Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Braveheart Bio and its competitors. Braveheart Bio's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Braveheart Bio stock overvalued right now?
Braveheart Bio (BRVE) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Braveheart Bio's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Braveheart Bio (BRVE), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Braveheart Bio Business Description

Comparable Companies
Address One Letterman Drive, Suite A4-300, Building A, San Francisco, CA, USA, 94129
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
8GF Score

Get the complete analysis for BRVE

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.93
Price